deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT04139317

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

A Randomized, Open Label, Multicenter Phase II Study Evaluating the Efficacy and Safety of Capmatinib (INC280) Plus Pembrolizumab Versus Pembrolizumab Alone as First Line Treatment for Locally Advanced or Metastatic Non-small Cell Lung Cancer With PD-L1≥ 50%

Sponsor: Novartis Pharmaceuticals

Conditions Non-small Cell Lung Cancer (NSCLC)
Interventions Capmatinib Pembrolizumab
Updated 27 times since 2019 Last updated: Oct 7, 2024 Started: Jan 22, 2020 Primary completion: Jan 14, 2022 Completion: Feb 7, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor decision to terminate due to the lack of tolerability observed in patients treated with capmatinib and pembrolizumab in the combination arm as compared to patients treated with pembrolizumab alone in the pembrolizumab single agent arm

Other terminated trials from Novartis Pharmaceuticals

See all terminations from Novartis Pharmaceuticals

Other Non-small Cell Lung Cancer (NSCLC) trials with similar outcome

Browse all Non-small Cell Lung Cancer (NSCLC) trials

A PHASE2 clinical study on Non-small Cell Lung Cancer (NSCLC), this trial is terminated or withdrawn. The trial is conducted by Novartis Pharmaceuticals and has accumulated 27 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Nov 2019 – ~Mar 2020 · 4 months · monthly snapshot~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Apr 2022 · 4 months · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Mar 2024 · 12 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Sep 2025 · 10 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

27 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Nov 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Sep 2024 — Nov 2024 [monthly]

    Terminated PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  5. Mar 2024 — Jul 2024 [monthly]

    Terminated PHASE2

▶ Show 22 earlier versions

  1. Mar 2023 — Mar 2024 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  2. Feb 2023 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2023 — Feb 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE2

  5. Nov 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE2

  6. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE2

  7. May 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  8. Apr 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE2

  9. Dec 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE2

  10. Nov 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2

  11. Oct 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE2

  12. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE2

  13. Jun 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  14. Apr 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  15. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  16. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  17. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  18. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  19. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  20. May 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

  21. Mar 2020 — May 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  22. Nov 2019 — Mar 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amersfoort, Netherlands , Ancona, Italy , Athens, Greece , Aviano, Italy , Badalona, Spain , Bangkok, Thailand , Barcelona, Spain , Berlin, Germany , Breda, Netherlands , Changhua, Taiwan and 23 more locations